Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Scandion Oncology
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Company description: Binary inflection point approaches === Founded in 2017 and based in Copenhagen, Denmark, Scandion Oncology is focused on developing novel solutions to address chemotherapy resistance in oncology. Management’s present development programme revolves around one asset, SCO-101, which is in trials investigating its use in the treatment of mCRC (Phase II) and PC (Phase Ib). SCO-101 is a first-in-class chemotherapy add-on that is designed to inhibit two well-documented mechanisms of chemotherapy resistance. Scandion’s hypothesis asserts that if these mechanisms are blocked, a chemotherapeutic response will be restored, and patients will see improved survival. There are currently no drugs targeting chemotherapy resistance on the market. Edison Investment Research's investment thesis rests on crucial proof-of-concept data from part 2 of the CORIST Phase II trial in last-line mCRC, following initial dose finding results from part 1 in 2021. Edison Investment Research expects Scandion demonstrating a clinically meaningful reversal of resistance to FOLFIRI in these patients could result in a material re-rating of the stock. Proof-of-concept data could, in turn, increase confidence in SCO-101’s second indication, PC, for which it is currently in a Phase Ib dose finding trial (PANTAX). Assuming positive results from CORIST part 2, Edison Investment Research believes the company will need to generate randomised data in mCRC in further trials to maximise the value of SCO-101 to potential partners/licensors, targeting the core US and European markets. To fund this, Edison Investment Research expects management would need to raise additional capital and/or pursue non-dilutive smaller, regional licensing deals. In the long term, Edison Investment Research sees the prospects of SCO-101 in other indications and combinations as potentially significant; data from the PANTAX study will be important in corroborating this view.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)